Pricing, Reimbursement At Center of China Industry Reform Pleas
This article was originally published in PharmAsia News
Executive Summary
Amid widening pessimism, Chinese domestic pharma executives have voiced few signs of relief at an annual "meet the regulators' session in which concerns are aired and candid views shared.
You may also be interested in...
2016 Review: Pricing, R&D Issues Dominate China Commercial Arena
2016 was again another busy year on the commercial front in China, with market changes, new regulations, and ongoing pricing pressures all affecting the pharma sector. Meanwhile, the push for licensing deals, innovation, and international expansion continued apace.
Ready, Set, Go: China To Use Patient-Reported Outcomes In Clinical Studies
As a part of real-world evidence, patient-reported outcomes can serve to evaluate a drug's efficacy against primary or secondary endpoints and also reflect safety and quality of life, notes a just-released draft regulation from China’s Center for Drug Evaluation.
Biotech Picks Up Pace In China While Investors Project Hong Kong Confidence
Beneath booming healthcare financing and deal-making in Asia is a constant flow of ready capital, but there are also challenges that may present hurdles to Hong Kong overtaking Nasdaq as the premier site for listings in the sector, a recent summit heard.